Epizyme’s Tazverik Gets To Market In Rare Sarcoma, Paving Way To Bigger Indications

 
• By Joseph Haas

Accelerated approval in epithelioid sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.

Text Starting Point and yellow pencil on bright background
Now that it has approval in ES, Epizyme will attempt to move Tazverik into larger indications

More from New Products

More from Scrip